30 Sep 2013 Business Update and Appendix 4C
Filed with ASX · · 8 pages · English
Cogstate (ASX.CGS) has today released its Appendix 4C – Quarterly Cash Flow statement for the quarter ended 30 September 2013. During the quarter, Cogstate recognised sales revenue of $2.7 million compared to $2 million for the September 2013 quarter, an increase of 35%. This revenue is largely derived from milestone payments relating to clinical trials contracts that are currently underway or com
Earlier from Cogstate
- Precision Recruitment chosen for phase III Alzheimers study
- Contracts signed since 1 July 2014 hit $9 million
- Cogstate Test to be used in large paediatric clinical trial
- Cogstate signs first client to Precision Recruitment
- Cogstate signs $7.3 million sales contract
Later from Cogstate
- CogState launches Cognigram test in Canada
- Growing recognition of Cogstate test as a cognitive tool
- Merck releases new data on effectiveness of Cognigram
- CogState partners with Merck Canada
- CogState Signs Contract For Phase 2 Schizophrenia Study
Follow Cogstate into a list and get an email when it puts out news.
Follow Cogstate